Tag: mAbs

Through our network of global connections, we aim to make knowledge not just available, but valuable. We want to help you acquire expertise that can be directly applied to your practice. Explore the various medical education resources below:


Immunotherapy Web Featured Images 77

T-cell engaging antibodies for hematological diseases from approved therapies to...

Are bispecific antibodies less effective (and less toxic) than CAR-T cells? This educational video from EHA25 congress shows us the race between CAR-T therapy and bispecific Abs for hematological diseases is still ongoing!

Visit website
Immunotherapy Web Featured Images 31

EHA-SWG Scientific Meeting on Immunotherapy: Multiple Myeloma - More than CAR-T

This selection of educational videos from the recent EHA-SWG Scientific Meeting on Immunotherapy address the latest and more innovative immune-therapeutic options for multiple myeloma patients - including bispecific antibodies, antibody-drug-conjugates and new immunomodulator drugs.

Read more
ImmunotherapyWebsite Images Featured 36

IACH Focus on Leukemia 2020 | Antibody-based therapy to treat AML: radioimmunoco...

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-based therapy in acute myeloid leukemia (AML).

Visit website
ImmunotherapyWebsite Images Featured 21

Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma

  Sep 17 2020 Tagged CAR-T, mAbs, MM

C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape.

Visit website